

Bexarotene capsules Targretin® (No. 14/02)

Elan Pharma
Summary of Recommendation

8 November 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland.

RECOMMENDATION

Bexarotene is recommended for use in Scotland as a second line treatment for patients with advanced (stages IIb or III) cutaneous T-cell lymphoma. Bexarotene treatment should normally be initiated and supervised by haematologists, dermatologists or oncologists and used for patients who have proved refractory both to local skin directed therapy and to at least one systemic treatment.

Professor David H Lawson
Chairman